| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3301308 | B | Inhibition of HPV-16 LCR transcriptional activity in human P21 cells at 100 uM after 24 hrs by luciferase reporter gene assay | Alphapapillomavirus 9 | 22 | ALA3297723 | cell-based format | Scientific Literature | |
| 2. | ALA3299274 | B | Inhibition of HPV-16 LCR transcriptional activity in human P21 cells at 30 uM after 24 hrs by luciferase reporter gene assay | Alphapapillomavirus 9 | 22 | ALA3297723 | cell-based format | Scientific Literature | |
| 3. | ALA3299275 | B | Inhibition of HPV-16 LCR transcriptional activity in human P21 cells after 24 hrs by luciferase reporter gene assay | Alphapapillomavirus 9 | 22 | ALA3297723 | cell-based format | Scientific Literature | |
| 4. | ALA3299276 | A | Drug uptake in human CaSki cells at 10 uM after 16 hrs by reverse-phase HPLC analysis | Homo sapiens | 6 | ALA3297723 | cell-based format | Scientific Literature | |
| 5. | ALA3299277 | A | Cytotoxicity against human P21 cells assessed as inhibition of cell viability after 24 hrs by CellTiter96 assay | Homo sapiens | 22 | ALA3297723 | cell-based format | Scientific Literature | |
| 6. | ALA3299278 | F | Selectivity index, ratio of CC50 for human P21 cells to IC50 for HPV-16 LCR transcriptional activity in human P21 cells | 15 | ALA3297723 | cell-based format | Scientific Literature | ||
| 7. | ALA3299281 | A | Cytotoxicity against human CaSki cells assessed as inhibition of cell proliferation at 10 uM after 24 hrs by CellTiter96 assay | Homo sapiens | 13 | ALA3297723 | cell-based format | Scientific Literature | |
| 8. | ALA3299282 | F | Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity | Human immunodeficiency virus 1 | 1 | ALA3297723 | organism-based format | Scientific Literature | |
| 9. | ALA3299283 | F | Antiviral activity against HRV infected in human MA104 cells assessed as protection against virus-induced cytopathogenicity | Rotavirus | 1 | ALA3297723 | organism-based format | Scientific Literature | |
| 10. | ALA3299361 | F | Antiviral activity against RSV infected in human Hep2 cells assessed as protection against virus-induced cytopathogenicity | Human respiratory syncytial virus | 1 | ALA3297723 | organism-based format | Scientific Literature | |
| 11. | ALA3299362 | F | Antiviral activity against HSV2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity | Human alphaherpesvirus 2 | 1 | ALA3297723 | organism-based format | Scientific Literature | |
| 12. | ALA3299363 | F | Antiviral activity against VSV infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity | Vesicular stomatitis virus | 1 | ALA3297723 | organism-based format | Scientific Literature | |
| 13. | ALA3299364 | A | Drug uptake in human CaSki cells at 10 uM after 1 hr by reverse-phase HPLC analysis | Homo sapiens | 6 | ALA3297723 | cell-based format | Scientific Literature | |
| 14. | ALA3299365 | A | Drug level in human CaSki cells treated with ethyl 7-[4-(1,3-Benzothiazol-2-yl)piperazin-1-yl]-1-(3-chloro-2- fluorobenzyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate at 10 uM after 16 hrs by reverse-phase HPLC analysis | Homo sapiens | 1 | ALA3297723 | cell-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!